JP2023511441A5 - - Google Patents
Info
- Publication number
- JP2023511441A5 JP2023511441A5 JP2022544753A JP2022544753A JP2023511441A5 JP 2023511441 A5 JP2023511441 A5 JP 2023511441A5 JP 2022544753 A JP2022544753 A JP 2022544753A JP 2022544753 A JP2022544753 A JP 2022544753A JP 2023511441 A5 JP2023511441 A5 JP 2023511441A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964932P | 2020-01-23 | 2020-01-23 | |
| US62/964,932 | 2020-01-23 | ||
| PCT/US2021/014302 WO2021150673A1 (en) | 2020-01-23 | 2021-01-21 | Gip/glp1 co-agonist compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025195273A Division JP2026069790A (ja) | 2020-01-23 | 2025-11-14 | Ｇｉｐ／ｇｌｐ１共アゴニスト化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511441A JP2023511441A (ja) | 2023-03-17 |
| JP2023511441A5 true JP2023511441A5 (https=) | 2024-01-25 |
| JPWO2021150673A5 JPWO2021150673A5 (https=) | 2024-01-25 |
Family
ID=74592824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544753A Pending JP2023511441A (ja) | 2020-01-23 | 2021-01-21 | Ｇｉｐ／ｇｌｐ１共アゴニスト化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230265151A1 (https=) |
| EP (1) | EP4093757A1 (https=) |
| JP (1) | JP2023511441A (https=) |
| KR (1) | KR20220131292A (https=) |
| CN (1) | CN115298207A (https=) |
| AR (1) | AR121093A1 (https=) |
| AU (1) | AU2021211451B2 (https=) |
| BR (1) | BR112022014397A2 (https=) |
| CA (1) | CA3165430A1 (https=) |
| IL (1) | IL294955A (https=) |
| MX (1) | MX2022009149A (https=) |
| TW (1) | TWI770781B (https=) |
| WO (1) | WO2021150673A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI912614B (zh) * | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| JP2024508745A (ja) * | 2021-02-17 | 2024-02-28 | イーライ リリー アンド カンパニー | Ｇｉｐ／ｇｌｐ１デュアルアゴニスト治療方法 |
| IL310377A (en) | 2021-08-30 | 2024-03-01 | Mindrank Ai Ltd | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| MX2024003236A (es) | 2021-09-15 | 2024-06-19 | Viking Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. |
| CN117586373A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
| CN116023444B (zh) * | 2022-08-12 | 2023-08-01 | 重庆宸安生物制药有限公司 | 一种gip和glp-1双受体激动剂多肽化合物及其应用 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| WO2012167744A1 (en) * | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| JP6228187B2 (ja) * | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| HK1211232A1 (en) * | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| MX2016005556A (es) * | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| JO3575B1 (ar) | 2015-01-09 | 2020-07-05 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| TWI783244B (zh) * | 2015-06-22 | 2022-11-11 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| CN112469731B (zh) * | 2018-07-23 | 2024-11-29 | 伊莱利利公司 | Gip/glp1共激动剂化合物 |
-
2021
- 2021-01-21 WO PCT/US2021/014302 patent/WO2021150673A1/en not_active Ceased
- 2021-01-21 AR ARP210100135A patent/AR121093A1/es unknown
- 2021-01-21 EP EP21705072.3A patent/EP4093757A1/en active Pending
- 2021-01-21 JP JP2022544753A patent/JP2023511441A/ja active Pending
- 2021-01-21 US US17/794,128 patent/US20230265151A1/en active Pending
- 2021-01-21 AU AU2021211451A patent/AU2021211451B2/en active Active
- 2021-01-21 IL IL294955A patent/IL294955A/en unknown
- 2021-01-21 TW TW110102332A patent/TWI770781B/zh active
- 2021-01-21 BR BR112022014397A patent/BR112022014397A2/pt unknown
- 2021-01-21 CA CA3165430A patent/CA3165430A1/en active Pending
- 2021-01-21 MX MX2022009149A patent/MX2022009149A/es unknown
- 2021-01-21 KR KR1020227028667A patent/KR20220131292A/ko not_active Withdrawn
- 2021-01-21 CN CN202180023819.8A patent/CN115298207A/zh active Pending